TOP: Tysabri® Observational Program

Trial Profile

TOP: Tysabri® Observational Program

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 13 Oct 2017

At a glance

  • Drugs Natalizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Acronyms TOP
  • Sponsors Biogen
  • Most Recent Events

    • 28 Apr 2017 Results assessing reasons patients discontinue natalizumab, subsequent therapies and post-discontinuation disease activity (n=2896), presented at the 69th Annual Meeting of the American Academy of Neurology
    • 28 Apr 2017 Results (n=556) assessing effect of inintiation time of natalizumab treatment on real-world outcomes in treatment naive multiple sclerosis patients, presented at the 69th Annual Meeting of the American Academy of Neurology
    • 24 Apr 2017 According to a Biogen media release, data was presented at the 69th annual meeting of the American Academy of Neurology (AAN)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top